利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.036 秒)

    Quinine derivatines
    4.
    发明授权
    Quinine derivatines 失效
    奎宁衍生物

    公开(公告)号：US4818441A

    公开(公告)日：1989-04-04

    申请号：US165009

    申请日：1980-07-01

    申请人： Isuke Imada ,  Shinji Terao ,  Mitsuru Kawada ,  Mitsuru Shiraishi

    发明人： Isuke Imada ,  Shinji Terao ,  Mitsuru Kawada ,  Mitsuru Shiraishi

    IPC分类号： A61K31/12 ,  A61K31/20 ,  A61P3/02 ,  A61P9/00 ,  A61P9/12 ,  A61P11/08 ,  C07C41/26 ,  C07C43/23 ,  C07C45/00 ,  C07C45/71 ,  C07C46/02 ,  C07C46/06 ,  C07C46/10 ,  C07C47/277 ,  C07C50/14 ,  C07C50/26 ,  C07C50/28 ,  C07C50/32 ,  C07C50/38 ,  C07C51/00 ,  C07C66/00 ,  C07C67/00 ,  C07C50/02

    CPC分类号： C07C66/00 ,  C07C41/26 ,  C07C41/48 ,  C07C45/71 ,  C07C46/02 ,  C07C46/06 ,  C07C46/10 ,  C07C47/277 ,  C07C50/28 ,  C07C50/32 ,  C07C50/38

    摘要： A compound of the general formul: ##STR1## wherein .alpha. .beta. means a saturated bond or a double bond; each R independently of one another is a methyl group or a methoxy group, or two R's taken together represent a group of --CH.dbd.CH--CH.dbd.CH--; n is zero or an integer of 1 through 9; when .alpha. .beta. is a saturated bond, R.sub.2 is a hydrogen atom or hydroxyl group, and when .alpha. .beta. is a double bond, R.sub.2 is a hydrogen atom; when .alpha. .beta. is a double bond or when R.sub.2 is a hydroxyl group, R.sub.1 is a carboxyl group, a group of CH.sub.2.sub.2m OH (wherein m is an integer of 1 through 3) or a group of ##STR2## (wherein m is an integer of 1 through 3); when .alpha. .beta. is a saturated bond and R.sup.2 is a hydrogen atom, R.sub.1 is a hydroxymethyl group or a group of ##STR3## (wherein m is an integer of 1 through 3) has pharmacological actions such as membrane stabilizing activity (e.g. lysosomal membrane stabilizing activity), mitochondrial electron transport activity, hypotensive activity, activity to inhibit cardiac hypertrophy, tracheal muscle relaxant activity, cerebral circulation improving activity and cerebral ischemia preventive activity and is of value in the prophylaxis and treatment of hypertension, cardiac failure, asthma, cerebral apoplexy and other diseases, as a cardiac failure remedy, bronchodilator, cerebral circulation improving agent or the like.

    摘要翻译： 一般化合物的化合物：其中αβ表示饱和键或双键; 每个R彼此独立地是甲基或甲氧基，或两个R一起表示-CH = CH-CH = CH-的基团; n为0或1〜9的整数; 当αβ是饱和键时，R2是氢原子或羟基，当αβ是双键时，R2是氢原子; 当αβ是双键时，或当R2是羟基时，R1是羧基，CH22mOH（其中m是1至3的整数）或一组（其中m是 1〜3）; 当αβ为饱和键且R 2为氢原子时，R 1为羟甲基或一组（其中m为1至3的整数）具有药物作用如膜稳定活性（例如溶酶体膜稳定 活性），线粒体电子传递活性，降血压活性，抑制心脏肥大的活性，气管肌松弛剂活性，脑循环改善活性和脑缺血预防活性，并且在预防和治疗高血压，心力衰竭，哮喘，脑中风中具有价值 和其他疾病，作为心力衰竭治疗，支气管扩张剂，脑循环改善剂等。

    Quinone derivatives, their production and use
    7.
    发明授权
    Quinone derivatives, their production and use 失效
    喹诺酮衍生物，其生产和使用

    公开(公告)号：US5229385A

    公开(公告)日：1993-07-20

    申请号：US818856

    申请日：1992-01-10

    申请人： Shinji Terao ,  Kohei Nishikawa

    发明人： Shinji Terao ,  Kohei Nishikawa

    IPC分类号： C07D213/50 ,  C07D213/55 ,  C07D409/06 ,  C07D521/00

    CPC分类号： C07D231/12 ,  C07D213/50 ,  C07D213/55 ,  C07D233/56 ,  C07D249/08 ,  C07D409/06

    摘要： Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is hydrogen atom or methyl group; R.sup.4 is nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or carboxyl group which may be esterified or amidated; Z is ##STR2## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in []), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therpeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.

    摘要翻译： 由通式（I）表示的醌酮衍生物（其中，R1和R2相同或不同，指氢原子，甲基或甲氧基甲基，或R1和R2结合在一起形成-CH = CH-CH = CH-; R3是氢原子或甲基; R4是可以被取代的含氮杂环基; R5是氢原子，甲基，可被取代的羟甲基，或可被酯化或酰胺化的羧基; Z是 （其中，R'为氢原子或甲基）; n为0〜12的整数，m为0〜3的整数，k为0〜7的整数， 当m为2或3时，Z和k能够在[]）所示的重复单元中适当变化，并且其氢醌衍生物是新型化合物，具有改善多不饱和脂肪酸代谢的效果，特别是两种或更多种 抑制脂肪酸过氧化物的产生，抑制代谢物的产生 在5-脂氧合酶途径中，血栓烷A2合成酶的抑制，血栓素A2受体拮抗作用和活性氧的清除作用，以及用作药物，如抗血栓形成剂，抗血管收缩剂，抗哮喘药，抗过敏剂，治疗剂 牛皮癣，改善心脏，脑和心血管系统的药剂，肾炎治疗剂，活性氧消除剂，抗癌剂，改善花生四烯酸级联产物的控制剂等。

    Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
    8.
    发明授权
    Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines 失效
    抑制3-（1-烯基）吡啶的血栓烷合成酶

    公开(公告)号：US4563446A

    公开(公告)日：1986-01-07

    申请号：US632332

    申请日：1984-07-19

    申请人： Shinji Terao ,  Kohei Nishikawa

    发明人： Shinji Terao ,  Kohei Nishikawa

    IPC分类号： C07D213/02 ,  C07D213/06 ,  C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/48 ,  C07D213/55 ,  C07D213/56 ,  C07D213/57 ,  C07D213/80 ,  C07D213/89 ,  C07D401/06 ,  C07D405/02 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D521/00 ,  C07F7/18 ,  C07D213/59 ,  C07D213/24 ,  A61K31/44

    CPC分类号： C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/48 ,  C07D213/55 ,  C07D213/56 ,  C07D213/57 ,  C07D213/80 ,  C07D213/89 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/06 ,  C07D409/06 ,  C07F7/1856

    摘要： Novel compounds of the formula: ##STR1## wherein R.sup.2 is an aromatic or heterocyclic group, which may optionally be substituted, R.sup.2 is a methyl group, a hydroxymethyl group, a nitroxymethyl group, a formyl group, a nitrogen-containing five-membered ring-methyl group, an acetal-methyl group, a trialkylsilyloxymethyl group, an alkyl- or aryl-sulfonyloxymethyl group, an alkyl- or aryl-sulfonylaminocarbonyloxymethyl group, an acyloxymethyl group, an alkoxycarbonyloxymethyl group, a halogenomethyl group, an alkoxymethyl group, an aryloxymethyl group, a cyano group, a carbamoyl group which may optionally be substituted, a carbamoyloxymethyl group which may optionally be substituted, a thiocarbamoyloxymethyl group which may optionally be substituted, and an alkoxycarbonyl group, n is an integer of 1 to 20, and ##STR2## provided that n is an integer of 9 to 20 when ##STR3## and, at the same time, R.sup.2 is a carboxyl group or an alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, have a selective inhibitory action on biosynthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of enhancing the production of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to prevent and treat arterial thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, stroke, occlusion of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

    摘要翻译： 下式的新型化合物：其中R 2为可任意取代的芳族或杂环基，R 2为甲基，羟甲基，硝酰甲基，甲酰基，含氮五元环 甲基，缩醛 - 甲基，三烷基甲硅烷氧基甲基，烷基 - 或芳基 - 磺酰氧基甲基，烷基 - 或芳基 - 磺酰基氨基羰基氧基甲基，酰氧基甲基，烷氧基羰氧基甲基，卤代甲基，烷氧基甲基， 基团，氰基，可以任意取代的氨基甲酰基，可任意取代的氨基甲酰氧基甲基，可任意取代的硫代氨基甲酰氧基甲基，烷氧基羰基，n为1〜20的整数，＆lt; IMAGE >条件是当中n为9〜20的整数，并且同时R2为羧基或烷氧基羰基时，或其药理学上可接受的盐具有 对血栓素A2（TXA2）的生物合成的选择性抑制作用和增强前列腺素I2（PGI2）的产生的作用，可用于哺乳动物预防和治疗血小板聚集或心脏血管痉挛引起的缺血性疾病引起的动脉血栓形成 ，脑和周围循环系统（例如， 心脏梗死，中风，肾脏，肺部和其他器官中血管闭塞，果胶性溃疡等）。

    Manufacturing method of semiconductor device and semiconductor manufacturing device
    9.
    发明申请
    Manufacturing method of semiconductor device and semiconductor manufacturing device 失效
    半导体器件和半导体制造器件的制造方法

    公开(公告)号：US20060057860A1

    公开(公告)日：2006-03-16

    申请号：US11207064

    申请日：2005-08-18

    申请人： Shinji Terao

    发明人： Shinji Terao

    IPC分类号： H01L21/31

    CPC分类号： H01L21/02238 ,  H01L21/02255 ,  H01L21/31662 ,  H01L21/67253

    摘要： A manufacturing method of a semiconductor device, comprises; a process of heat-treating a semiconductor substrate under the ordinary pressure and in an oxidizing atmosphere; and a process of heat-treating the semiconductor substrate under the ordinary pressure and in an inert atmosphere, wherein heat-treating time or heat-treating temperature in heat treatment in the oxidizing atmosphere is changed based on the fluctuation of atmospheric pressure, and the heat-treating time in the inert atmosphere is determined based on the heat-treating time or the heat-treating temperature in the oxidizing atmosphere.

    摘要翻译： 一种半导体器件的制造方法，包括： 在常压和氧化气氛中对半导体衬底进行热处理的工艺; 以及在常压下和惰性气氛下对半导体基板进行热处理的工序，其中氧化气氛中的热处理时间或热处理温度根据大气压的波动而变化，热量 基于氧化气氛中的热处理时间或热处理温度来确定惰性气氛中的时间。